Cogent Biosciences, Inc. (COGT) News

Cogent Biosciences, Inc. (COGT): $9.02

0.15 (+1.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add COGT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter COGT News Items

COGT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest COGT News From Around the Web

Below are the latest news stories about Cogent Biosciences Inc that investors may wish to consider to help them evaluate COGT as an investment opportunity.

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | February 1, 2022

Analysts’ Top Healthcare Picks: Albireo Pharma (ALBO), Cogent Biosciences (COGT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma (ALBO – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments. Albireo Pharma (ALBO) Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma today and set a price target of $84.00. The company's shares closed last Wednesday at $24.31. According to TipRanks.

Brian Anderson on TipRanks | January 6, 2022

Cogent Biosciences Provides 2022 Corporate Guidance

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided 2021 year-end updates and corporate guidance for 2022.

Yahoo | January 5, 2022

Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President will participate in a fireside chat and one-on-one investor meetings during the Piper Sandler 33rd Annual Healthcare Conference, taking place virtually November 29 – December 2, 2021.

Yahoo | November 22, 2021

Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the third quarter ended September 30, 2021 and provided corporate updates.

Yahoo | November 10, 2021

Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.

Yahoo | November 2, 2021

Hedge Funds Are Dumping Cogent Biosciences, Inc. (COGT)

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

Yahoo | October 29, 2021

2 “Strong Buy” Stocks Under $10 With Over 100% Upside Potential

For investors seeking the best returns, the decision of where to put the initial investment typically comes down to two choices. Put all the eggs in one big basket, and buy into the market’s giant corporations, the trillion-dollar companies with famously high share prices and a track record of steady growth – or to buy low, find a group of low-cost stocks in companies with sound business footings and high potential upside. It all comes down to just how much of a return do you want. The market's three biggest companies, Apple, Microsoft, and Google, have upsides running between 10% and 20% for the year ahead.

Michael Marcus on TipRanks | October 12, 2021

Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain Penetration

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data providing further evidence of bezuclastinib as a differentiated, potent, and selective KIT inhibitor. The data were presented in a virtual poster at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

Yahoo | October 7, 2021

Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the Company will present preclinical data on bezuclastinib at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics held October 7-10, 2021.

Yahoo | October 1, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5956 seconds.